- Investing Ideas
- Japanese Pharmaceuticals & Biotech Healthy high growth potential
Japanese Pharmaceuticals & Biotech Healthy high growth potential
Results
2
0 new
Analysts expect these companies to experience strong growth in earnings over the next 3 years. They also meet criteria around being in an acceptable financial position.
2 companies
Healios K.K
Market Cap: JP¥34.7b
Engages in the research, development, manufacturing, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States.
4593
JP¥257.00
7D
3.6%
1Y
-38.2%
SanBio
Market Cap: JP¥78.9b
Engages in the development, production, and sale of regenerative cell medicines for the central nervous system.
4592
JP¥1,011.00
7D
5.6%
1Y
-53.5%